Jay A Messer1, Ekim Ekinci2, Tejal A Patel3, Bin S Teh4. 1. Department of Radiation Oncology, The University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0711, USA. 2. Department of Pharmacy, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX 77030, USA. 3. Department of Internal Medicine, Hematology/Oncology Division, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX 77030, USA. 4. Department of Radiation Oncology, Houston Methodist Hospital, 6565 Fannin Street, Houston, TX 77030, USA.
Abstract
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a new class of targeted therapy options for the treatment of estrogen receptor-positive (ER+) human epidermal growth factor 2-negative (HER2-) metastatic breast cancer. There are currently no published prospective data on the safety of use of radiation treatment with palbociclib. CASE: We describe the case of a patient with metastatic breast cancer who received radiation treatment to a metastatic supraclavicular lymph node to planned 60 Gy in 30 fractions while on palbociclib, a selective inhibitor of CDK4/6. The patient developed early radiation toxicities including esophagitis and dermatitis that progressed to a severe left neck skin breakdown in the radiation field, resulting in the need for hospitalization. She had a break in treatment but was able to finish the radiation without palbociclib. Her tumor responded well to the treatment and her side effects healed. DISCUSSION: To our knowledge this is the first case to report on concurrent palbociclib and radiation use, with resultant enhanced radiation effects that required hospitalization for symptom management. Several preclinical studies have shown synergistic effects of radiation and both in vivo and in vitro experiments resulting in improved survival and decreased cell proliferation, respectively, through enhanced G1 cell cycle arrest. CONCLUSION: This case highlights the importance of using caution when combining radiation with the new targeted therapies. Until more data becomes available, physicians are recommended to exercise clinical judgment when deciding on whether to continue or discontinue a CDK4/6 inhibitor in a patient who may need radiation.
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a new class of targeted therapy options for the treatment of estrogen receptor-positive (ER+) human epidermal growth factor 2-negative (HER2-) metastatic breast cancer. There are currently no published prospective data on the safety of use of radiation treatment with palbociclib. CASE: We describe the case of a patient with metastatic breast cancer who received radiation treatment to a metastatic supraclavicular lymph node to planned 60 Gy in 30 fractions while on palbociclib, a selective inhibitor of CDK4/6. The patient developed early radiation toxicities including esophagitis and dermatitis that progressed to a severe left neck skin breakdown in the radiation field, resulting in the need for hospitalization. She had a break in treatment but was able to finish the radiation without palbociclib. Her tumor responded well to the treatment and her side effects healed. DISCUSSION: To our knowledge this is the first case to report on concurrent palbociclib and radiation use, with resultant enhanced radiation effects that required hospitalization for symptom management. Several preclinical studies have shown synergistic effects of radiation and both in vivo and in vitro experiments resulting in improved survival and decreased cell proliferation, respectively, through enhanced G1 cell cycle arrest. CONCLUSION: This case highlights the importance of using caution when combining radiation with the new targeted therapies. Until more data becomes available, physicians are recommended to exercise clinical judgment when deciding on whether to continue or discontinue a CDK4/6 inhibitor in a patient who may need radiation.
Entities:
Keywords:
Breast cancer; Palbociclib; Radiosensitizing; Radiotherapy
Authors: Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: Zhen Tao; Justin M Le Blanc; Chenguang Wang; Tingting Zhan; Hongqing Zhuang; Ping Wang; Zhiyong Yuan; Bo Lu Journal: Clin Cancer Res Date: 2016-01-01 Impact factor: 12.531
Authors: Steven H Lin; Jing Zhang; Uma Giri; Clifford Stephan; Mary Sobieski; Ling Zhong; Kathy A Mason; Jessica Molkentine; Howard D Thames; Stephen S Yoo; John V Heymach Journal: J Thorac Oncol Date: 2014-07 Impact factor: 15.609
Authors: Susan L Whiteway; Peter S Harris; Sujatha Venkataraman; Irina Alimova; Diane K Birks; Andrew M Donson; Nicholas K Foreman; Rajeev Vibhakar Journal: J Neurooncol Date: 2012-11-09 Impact factor: 4.130
Authors: Kelly L Barton; Katherine Misuraca; Francisco Cordero; Elena Dobrikova; Hooney D Min; Matthias Gromeier; David G Kirsch; Oren J Becher Journal: PLoS One Date: 2013-10-02 Impact factor: 3.240
Authors: C E S Comstock; M A Augello; J F Goodwin; R de Leeuw; M J Schiewer; W F Ostrander; R A Burkhart; A K McClendon; P A McCue; E J Trabulsi; C D Lallas; L G Gomella; M M Centenera; J R Brody; L M Butler; W D Tilley; K E Knudsen Journal: Oncogene Date: 2013-05-27 Impact factor: 9.867
Authors: Erin F Gillespie; Noah J Mathis; Max Vaynrub; Ernesto Santos Martin; Rupesh Kotecha; Joseph Panoff; Andrew L Salner; Alyson F McIntosh; Ranju Gupta; Amitabh Gulati; Divya Yerramilli; Amy J Xu; Meredith Bartelstein; David M Guttmann; Yoshiya J Yamada; Diana Lin; Kaitlyn Lapen; Deborah Korenstein; David G Pfister; Allison Lipitz-Snyderman; Jonathan T Yang Journal: Clin Transl Radiat Oncol Date: 2022-04-26
Authors: Martina Silvestri; Antonio Cristaudo; Aldo Morrone; Claudia Messina; Luigi Bennardo; Steven Paul Nisticò; Maria Mariano; Norma Cameli Journal: Drug Saf Date: 2021-05-06 Impact factor: 5.606
Authors: Andrea M Pesch; Nicole H Hirsh; Benjamin C Chandler; Anna R Michmerhuizen; Cassandra L Ritter; Marlie P Androsiglio; Kari Wilder-Romans; Meilan Liu; Christina L Gersch; José M Larios; Lori J Pierce; James M Rae; Corey W Speers Journal: Clin Cancer Res Date: 2020-09-23 Impact factor: 12.531
Authors: Evert S M van Aken; Aart Beeker; Ilse Houtenbos; Floris J Pos; Sabine C Linn; Paula H M Elkhuizen; Monique C de Jong Journal: Cancer Rep (Hoboken) Date: 2021-06-18